Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET
Company Participants
Meredith Kaya - Senior Vice President, Investor Relations and Strategic Finance
Dr. Cedric Francois - Co-Founder and CEO
Adam Townsend - Chief Commercial Officer
Dr. Caroline Baumal - Chief Medical Officer
Tim Sullivan - Chief Financial Officer
Conference Call Participants
Madhu Kumar - Goldman Sachs
Jon Miller - Evercore
Tazeen Ahmad - BofA
Anupam Rama - JPMorgan
Colleen Kusy - Baird
Yigal Nochomovitz - Citigroup
Steven Seedhouse - Raymond James
Phil Nadeau - TD Cowen
Justin Kim - Oppenheimer
Derek Archila - Wells Fargo
Eliana Merle - UBS
Annabel Samimy - Stifel
Joseph Stringer - Needham & Company
Douglas Tsao - H.C. Wainwright
Operator
Good day and thank you for standing-by. Welcome to the Q1 2023 Apellis Pharmaceuticals Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
Please be advised that today’s conference is being recorded. I’d now like to hand the conference over to your speaker today, Meredith Kaya. Please go ahead.
Meredith Kaya
Good afternoon. And thank you for joining us to discuss Apellis’ first quarter 2023 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Commercial Officer, Adam Townsend; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan.
Before we begin, I’d like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
Now I will turn the call over to Cedric.
Dr. Cedric Francois
Thank you, Meredith, and thank you all for joining us today. I know that the launch of SYFOVRE is top of mind for everyone, so let me jump right in. We received FDA approval of SYFOVRE for the treatment of geographic atrophy on February 17th. SYFOVRE is the first and only treatment available for GA, a disease that affects more than 1 million patients in the U.S. alone and that relentlessly and inevitably leads to vision loss.
Prescribing label details SYFOVRE’s proven ability to slow GA progression with increasing effects over a 24-month period, flexible dosing and a well demonstrated safety profile following nearly 12,000 injections.